MDGL · Company research
Madrigal Pharmaceuticals, Inc. Common Stock (MDGL): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits | Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo Stocktwits | View source ↗ | Stocktwits | Oct 16, 2026 | neutral | 0 | 0.6 |
| Stock awards for 26 new hires vest in four yearly installments at Madrigal - Stock Titan | Stock awards for 26 new hires vest in four yearly installments at Madrigal Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug - Stocktwits | MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug Stocktwits | View source ↗ | Stocktwits | Oct 11, 2026 | neutral | 0 | 0.6 |
| Madrigal Pharmaceuticals (MDGL) Stock Trades At A Discount Following A Very Large 5 Year Run - Yahoo Finance | Madrigal Pharmaceuticals (MDGL) Stock Trades At A Discount Following A Very Large 5 Year Run Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Madrigal Pharmaceuticals (MDGL) Genetics Update Keeps Fair Value In Focus - Yahoo Finance | Madrigal Pharmaceuticals (MDGL) Genetics Update Keeps Fair Value In Focus Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care? | Novo Nordisk is expanding semaglutide into new indications like MASH and obesity-related conditions to diversify revenue beyond its core GLP-1 franchise. However, the company faces significant competitive pressure from Eli Lilly's broad incretin portfolio expansion and other competitors in the MASH market. Novo's stock has underperformed the industry year-to-date, trading at a discount valuation with a Hold rating. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.5 | 1 |
| Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care? | Novo Nordisk is expanding semaglutide into new indications like MASH and obesity-related conditions to diversify revenue beyond its core GLP-1 franchise. However, the company faces significant competitive pressure from Eli Lilly's broad incretin portfolio expansion and other competitors in the MASH market. Novo's stock has underperformed the industry year-to-date, trading at a discount valuation with a Hold rating. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.5 | 1 |
| A liver drug improved disease measures across several genetic risk groups - Stock Titan | A liver drug improved disease measures across several genetic risk groups Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| Madrigal Pharmaceuticals (NasdaqGS:MDGL) Stock Forecast & Analyst Predictions - Simply Wall Street | Madrigal Pharmaceuticals (NasdaqGS:MDGL) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Sep 24, 2026 | neutral | 0 | 0.6 |
| Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off - The Motley Fool | Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off The Motley Fool | View source ↗ | The Motley Fool | Aug 25, 2026 | neutral | 0 | 0.6 |
| Madrigal Pharmaceuticals (MDGL) Stock Grapples With Widening Losses Despite Rezdiffra Growth - Simply Wall Street | Madrigal Pharmaceuticals (MDGL) Stock Grapples With Widening Losses Despite Rezdiffra Growth Simply Wall Street | View source ↗ | Simply Wall Street | Jul 31, 2026 | neutral | 0 | 0.6 |
| Madrigal: I Can't Bet Against A Company Performing This Well (Upgrade) - Seeking Alpha | Madrigal: I Can't Bet Against A Company Performing This Well (Upgrade) Seeking Alpha | View source ↗ | Seeking Alpha | Jul 31, 2026 | neutral | 0 | 0.6 |
| Madrigal Pharmaceuticals (MDGL) Beat Earnings Estimates, Is It Still Below Fair Value? - Yahoo Finance | Madrigal Pharmaceuticals (MDGL) Beat Earnings Estimates, Is It Still Below Fair Value? Yahoo Finance | View source ↗ | Yahoo Finance | Jul 31, 2026 | neutral | 0 | 0.6 |
| Madrigal Pharmaceuticals Shares Slide as Investors Reassess a High Earnings Bar | MDGL Stock News - Quiver Quantitative | Madrigal Pharmaceuticals Shares Slide as Investors Reassess a High Earnings Bar | MDGL Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 30, 2026 | neutral | 0 | 0.6 |
| Madrigal management to discuss Q2 results at 8 a.m. Eastern July 30 - Stock Titan | Madrigal management to discuss Q2 results at 8 a.m. Eastern July 30 Stock Titan | View source ↗ | Stock Titan | Jul 16, 2026 | neutral | 0 | 0.6 |
| Lobbying Update: $120,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed | MDGL Stock News - Quiver Quantitative | Lobbying Update: $120,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed | MDGL Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 15, 2026 | neutral | 0 | 0.6 |
| MDGL Forecast — Price Target — Prediction for 2027 - TradingView | MDGL Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| Madrigal Pharmaceuticals (MDGL) slides as insider sale headlines hit and investors take profits | MDGL Stock News - Quiver Quantitative | Madrigal Pharmaceuticals (MDGL) slides as insider sale headlines hit and investors take profits | MDGL Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Jun 2, 2026 | neutral | 0 | 0.6 |
| Madrigal Pharmaceuticals Stock Could Become The Next Vertex (NASDAQ:MDGL) - Seeking Alpha | Madrigal Pharmaceuticals Stock Could Become The Next Vertex (NASDAQ:MDGL) Seeking Alpha | View source ↗ | Seeking Alpha | Jun 2, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.